Let me verify the Conformis case details and settlement.
Medacta International SA is a Swiss orthopedics and neurosurgery device company headquartered at Strada Regina, 6874 Castel San Pietro, Switzerland. It was founded in 1999 by Dr. Alberto Siccardi, an orthopedic patient, and is the principal operating subsidiary of Medacta Group SA, which is listed on the SIX Swiss Exchange (ticker MOVE) and included in the Swiss Performance Index. Group FY2024 revenue was €590.6 million; FY2025 revenue was €683.8 million with roughly 2,165 employees, per company annual-report figures. Market capitalization was about CHF 3.1 billion at the end of 2025. It is a public operating company, not an NPE.
Products and operations. Medacta designs, manufactures and distributes orthopedic and spinal implants plus the associated instrumentation and surgical techniques, selling in over 40–70 countries. Product lines include hip replacement (notably its AMIS anterior minimally invasive surgery platform), knee replacement (GMK SpheriKA and the MyKA kinematic-alignment platform, plus MyKnee patient-matched cutting blocks), extremities covering shoulder systems and sports medicine, and spine systems featuring the NextAR augmented-reality surgical navigation application. It also runs the M.O.R.E. Institute for surgeon education and acquired Parcus Medical, a Florida sports-medicine and arthroscopy provider, in 2025.
Patent-litigation posture. Medacta appears in the tracked data as a pure defendant: one case, zero as plaintiff. That pattern is consistent with an operating company being accused of infringement rather than an entity monetizing patents. The single tracked suit, Conformis, Inc. v. Medacta USA, Inc. et al., was filed 2019-08-29 in the District of Delaware — a common venue for medical-device patent suits, not a plaintiff-friendly Eastern District of Texas filing.
Notable case context. Conformis asserted U.S. patents on patient-specific instrumentation ('129, '304, '161, '482) against Medacta's MyKnee and MyShoulder guides; Medacta moved for summary judgment of non-infringement in June 2022. The parties settled in November 2022: Medacta received a non-exclusive license to certain Conformis patient-specific-instrumentation patents and paid a low-single-digit million-dollar sum. A parallel Conformis suit against Medacta Europe in Düsseldorf over a German PSI patent (filed October 2021) was resolved by the same agreement. Medacta separately settled a MicroPort Orthopedics patent and tortious-interference suit in July 2021.